Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 39.00
+1.60 (4.28%)
May 29, 2026, 1:30 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 10.33 billion as of May 29, 2026. Its market cap has decreased by -26.05% in one year.
Market Cap
10.33B
Enterprise Value
11.57B
Revenue
483.94M
Ranking
n/a
PE Ratio
n/a
Stock Price
39.00
Market Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 10.33B, a decrease of -38.38%. That is a compound annual growth rate of -4.38%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 29, 2026 | 10.33B | -29.05% |
| Dec 31, 2025 | 14.56B | 36.15% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| CHO Pharma | 13.87B |
| TaiMed Biologics | 12.87B |
| EirGenix | 12.76B |
| Polaris Group | 12.21B |
| Ever Supreme Bio Technology | 12.09B |
| Locus Cell | 10.78B |
| AP Biosciences | 10.74B |
| Gongwin Biopharm Holdings | 8.80B |